Q4 2025 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) achieved $726 million in revenue for 2025, marking the highest gross margins in the company's history.
- The company has a clear strategic direction with its '5 by 30' strategy, aiming to help 3 million patients annually by 2030, and is already at 2.5 million.
- Pacira BioSciences Inc (PCRX) has secured a volume-limited settlement with Braznius, providing runway visibility for its flagship product, Xperel, through 2039.
- The company has expanded its patent protection to 21 patents across two families, strengthening its intellectual property estate.
- Significant partnerships with LG Chem and JJ MedTech are expected to open new markets and enhance product reach, with revenues from these agreements anticipated to begin in 2027.
- Despite the growth, the company faces challenges with flat sales for Zilreta in 2025, attributed to restructuring and sales force disruptions.
- Unexpected business development and litigation costs impacted the fourth quarter's SG&A expenses, increasing them to $91.9 million from $70.6 million in 2024.
- The company anticipates potential headwinds in elective procedures, which could affect revenue growth in 2026.
- The phase two study of PCRX 201 is primarily focused on safety and not powered for efficacy, which may delay the demonstration of clinical benefits.
- Pacira BioSciences Inc (PCRX) is experiencing a disconnect in market valuation, prompting opportunistic stock repurchases to address this issue.
Good day and thank you for standing by. Welcome to the Q4 2025 Pasir Biosciences earnings conference call. At this time, all participants are in a listen-only mode.
After the speaker's presentation, there will be a question-and-answer session.
To ask a question during this session, you will need to press 11 on your telephone.
You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Susan Mesko, head of investor relations. Please go ahead.
Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our fourth quarter and full year 2025 financial results. Joining me are Frank Lee, Chief Executive Officer, Brendan Tehan, Chief Commercial Officer, and Sean Cross, Chief Financial Officer. Before we begin, let me remind you that this call will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
